Symptoms and diagnostic delay in ovarian cancer: a summary of the literature
- PMID: 20230172
- DOI: 10.5172/conu.2009.34.1.055
Symptoms and diagnostic delay in ovarian cancer: a summary of the literature
Abstract
Ovarian cancer is the most common cause of death due to gynaecological cancers in developed countries. The symptoms of ovarian cancer are common female complaints, are non-specific and do not fit any easily recognisable pattern. This frequently leads to a delay in diagnosis. Until an effective screening test becomes available for this disease, increasing the education of women and clinicians regarding the symptoms of ovarian cancer must be seen as a priority. Nurses are ideally placed to disseminate information about the symptoms of ovarian cancer to the community and have a responsibility to do so. It is crucial that nurses are aware of the common symptoms and the usual diagnostic pathway in order to provide empathetic, informed nursing care. This paper draws on the results of a narrative systematic review to describe current knowledge of symptoms of ovarian cancer and describes delays women commonly experience in obtaining a diagnosis.
Similar articles
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280. Health Technol Assess. 2001. PMID: 11701100
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320. Health Technol Assess. 2001. PMID: 12065068
-
Antidepressants for pain management in adults with chronic pain: a network meta-analysis.Health Technol Assess. 2024 Oct;28(62):1-155. doi: 10.3310/MKRT2948. Health Technol Assess. 2024. PMID: 39367772 Free PMC article.
-
Patient-doctor communication.Med Clin North Am. 2003 Sep;87(5):1115-45. doi: 10.1016/s0025-7125(03)00066-x. Med Clin North Am. 2003. PMID: 14621334
-
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2. Cochrane Database Syst Rev. 2022. PMID: 36161421 Free PMC article.
Cited by
-
Ovarian Cancer Symptom Clusters: Use of the NIH Symptom Science Model for Precision in Symptom Recognition and Management.Clin J Oncol Nurs. 2022 Sep 15;26(5):533-542. doi: 10.1188/22.CJON.533-542. Clin J Oncol Nurs. 2022. PMID: 36108208 Free PMC article. Review.
-
A benzimidazolium salt induces apoptosis and arrests cells at sub-G1 phase in epithelial ovarian cancer cells.Mol Biol Rep. 2024 Jan 3;51(1):66. doi: 10.1007/s11033-023-08981-6. Mol Biol Rep. 2024. PMID: 38170294
-
Circulating Cell Free DNA as the Diagnostic Marker for Ovarian Cancer: A Systematic Review and Meta-Analysis.PLoS One. 2016 Jun 2;11(6):e0155495. doi: 10.1371/journal.pone.0155495. eCollection 2016. PLoS One. 2016. PMID: 27253331 Free PMC article.
-
Current Treatments and New Possible Complementary Therapies for Epithelial Ovarian Cancer.Biomedicines. 2021 Dec 31;10(1):77. doi: 10.3390/biomedicines10010077. Biomedicines. 2021. PMID: 35052757 Free PMC article. Review.
-
RNA m5C modification upregulates E2F1 expression in a manner dependent on YBX1 phase separation and promotes tumor progression in ovarian cancer.Exp Mol Med. 2024 Mar;56(3):600-615. doi: 10.1038/s12276-024-01184-4. Epub 2024 Mar 1. Exp Mol Med. 2024. PMID: 38424195 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical